RapidAI Archives - Medical Design Sourcing

FDA clears pulmonary embolism diagnostic, triage tech from RapidAI

RapidAI announced that it received FDA 510(k) clearance for its Rapid RV/LV tool for detecting pulmonary embolism (PE) severity.

San Mateo, California-based RapidAI designed Rapid RV/LV to quickly assess the ratio between right ventricle and left ventricle. This RV/LV metric represents a key indicator of PE severity. Automating the process enables the care team to more quickly prioritize patients and accelerate decision-making.

Rapid RV/LV uses artificial intelligence (AI) to analyze computerized tomography pulmonary angiograms (CTPAs). It automatically calculates the RV/LV ratio within minutes. The system comprises part of the Rapid PE triage and notification product. With combined results, PE teams can make faster care decisions and communicate for truly coordinated care.

The platform offers quick identification of patients with possible right heart strain and reduces time to diagnosis. RapidAI said in a news release it reduces variability and standard…

RapidAI wins Frost & Sullivan innovation award

Frost & Sullivan announced today that it recognized RapidAI with its 2022 Global Technology Innovation Leadership Award.

RapidAI develops artificial intelligence (AI) algorithms for treating vascular and neurovascular conditions. It offers solutions for stroke diagnosis and triage. Its AI creates high-quality, advanced brain images from non-contrast CT, CT angiography, CT perfusion and MRI diffusion and perfusion studies.

Frost & Sullivan said in a news release that the company “refined its holistic approach to care for life-threatening neurovascular and vascular conditions.” It continues to build a comprehensive software platform aimed to bridge the gaps in care.

The RapidAI platform offers value to a number of hospital environments and applications. Its technology can be used across emergency departments and trauma centers to acute stroke-ready hospitals, primary stroke centers and comprehensive stroke centers.

RapidAI design…

FDA clears RapidAI platform for assessing neuro injury severity

RapidAI announced today that it received FDA clearance for its Rapid Hyperdensity, a new addition to its RapidAI platform.

San Mateo, California-based RapidAI designed Rapid Hyperdensity to give physicians a tool to quickly assess the severity of injury in patients with acute neuro conditions, such as traumatic brain injury and brain hemorrhages, to allow for better and faster patient care decisions.

The artificial intelligence (AI)-powered Rapid Hyperdensity platform uses non-contrast CT scans to quickly assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage.

According to a news release, Rapid Hyperdensity provides additional contextual data to help physicians make more informed triage and transfer decisions to get patients to the right place in a more efficient manner.

“Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemor…

FDA clears RapidAI’s pulmonary embolism triage platform

RapidAI announced today that it received FDA 510(k) clearance for its Rapid PE Triage & Notification product.

San Mateo, California-based RapidAI designed its Rapid PE Triage & Notification product for the fast identification and communication of suspected central pulmonary embolism (PE).

According to a news release, Rapid PE Triage & Notification works in conjunction with RapidAI’s Rapid Workflow for PE offering. Rapid Workflow for PE, which the company designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, was launched in June 2021.

The company said its newly cleared platform will enable care teams to more easily manage the entire patient care journey from the moment a suspected PE patient is identified to diagnosis and through treatment. Patients can be triaged faster and care teams can be aligned more quickly to reduce the overall time to treatment thanks to the automatic identificati…

RapidAI launches workflow platform for pulmonary embolism

RapidAI announced today that it launched its mobile and web-based app to aid in the treatment of pulmonary embolism (PE).

San Mateo, Calif.-based RapidAI made available the Rapid Workflow for PE, which it designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, according to a news release.

Rapid Workflow for PE helps hospital teams align, activate and communicate about patient status to ensure faster care, reducing the time to treatment, improving care coordination and optimizing protocols through the collection of patient status data.

“Rapid Workflow for PE is the next step in our journey to improving patient care,” RapidAI CEO Don Listwin said in the release. “When it comes to acute vascular diseases, time is of the essence. That’s why we’ve created an extensible platform that addresses the specific needs of care teams across vascular and neurovascular conditions, providing these teams with the tools they …

FDA clears RapidAI blood clot detector

RapidAI announced today that it received FDA clearance for its Rapid LVO system for detecting suspected large vessel occlusions (LVOs).

Menlo Park, Calif.-based RapidAI’s Rapid LVO is designed to help physicians speed up triage or transfer decision making. The system uses a vessel tracker, along with an assessment of brain regions with reduced blood vessel density to identify suspected LVOs in as few as three minutes before immediately notifying stroke team members, according to a news release.

According to the company, which touts the system as the “gold standard” of cerebrovascular imaging, Rapid LVO can identify suspected LVOs with a sensitivity of 97%, as well as a specificity of 96%.

“LVOs are the most disabling and deadly ischemic strokes,” Stanford University professor of neurology, director of the Stanford Stroke Center & RapidAI co-founder Dr. Greg Albers said in the release. “The ability to identify LVOs rapidly facilitate…